MNLP – Module 5 – Final assessment

1. Question

Which of the following treatment combinations is not used as induction treatment prior to stem cell transplantation

A. Cyclophosphamide, thalidomide, dexamethasone
B. Velcade, thalidomide, dexamethasone
C. Cyclophosphamide, Velcade dexamethasone
D. Melphalan, prednisolone, thalidomide

2. Question

Which of the following statements is not true.

The aim of treatment is to:

A. Prolong survival
B. Maximise quality of life
C. Control the myeloma for as long as possible
D. Reduce the levels of the myeloma as little as possible
E. Relieve symptoms and reduce complications as much as possible

3. Question

Treatment of myeloma currently takes into account the following factors except for

A. Age
B. Presence or absence of symptoms and complications
C. Patient preference
D. Cytogenetic profile
E. Stage of disease

4. Question

Several classes of drugs are used to treat myeloma. Can you match the drug to the correct class?

Sort elements

Immunomodulatory drug
Alkylating chemotherapy agent
Corticosteroid
Proteasome inhibitor

Thalidomide
Cyclophosphamide
Dexamethasone
Velcade

5. Question

Match the correct terms to the following statement

Sort elements

older and/or less fit myeloma patients
younger and/or fitter myeloma patients

Non-intensive treatment is recommended for
while intensive treatment is recommended for

6. Question

Abbreviations are commonly used to describe anti-myeloma treatment combinations. What drugs make up VCD?

A. Pomalidomide, Adriamycin, dexamethasone
B. Prednisolone, Adriamycin, dexamethasone
C. Velcade, cyclophosphamide, dexamethasone
D. Velcade and dexamethasone
E. Pomalidomide and dexamethasone

7. Question

Complete the following statement

It is necessary for all patients who are prescribed thalidomide to be registered on a risk management programme because

A. It is common practice with all cancer treatments
B. It is a teratogen
C. It is a tetracycline
D. None of the above
E. All of the above

8. Question

Which of the following is not considered to be a contraindication to thalidomide

A. Creatinine clearance > 30 ml/min
B. Creatinine clearance < 30ml/min
C. Thrombophilia or a history of severe thrombosis
D. Pregnancy or patients of child-bearing age unable to follow or comply with the required contraceptive measures
E. Allergic to thalidomide

9. Question

Intensive treatment involves

A. High-dose chemotherapy given as a one off
B. High-dose chemotherapy given weekly until disease progression
C. High-dose chemotherapy followed by stem cell transplantation
D. High-dose chemotherapy followed by consolidation treatment
E. High-dose chemotherapy followed by maintenance treatment

10. Question

The approval of Velcade as a treatment for relapsed myeloma was based on which pivotal trial?

A. Myeloma XI
B. Myeloma IX
C. MUK one
D. APEX
E. MM-009

11. Question

The favoured route of Velcade administration is

A. Oral
B. Subcutaneous
C. Intramuscular
D. Intravenous
E. Intrathecal

12. Question

Revlimid is licensed for use in combination with which drug for relapsed myeloma patients?

A. Prednisolone
B. Dexamethasone
C. Cyclophosphamide
D. Melphalan
E. Adriamycin

13. Question

Type in the words short-term, long-term, sustaining, maximising to complete the following definitions.

Maintenance treatment is treatment administered with the aim of control of the myeloma.
Consolidation treatment is treatment administered with the aim of the depth of response to a previous treatment.

14. Question

Assertion: High-dose chemotherapy and stem cell transplantation is used to treat myeloma

BECAUSE

Reason: Conventional chemotherapy is unable to provide a deep and durable response for many patients

A. True True – reason correctly explains assertion
B. True True – both statements are true but the reason does not explain the assertion
C. True False
D. False True
E. False False

15. Question

Assertion: Remission periods generally lengthen with subsequent treatments

BECAUSE

Reason: Acquired drug resistance is the reason why patients ultimately become refractory to treatment

A. True True – reason correctly explains assertion
B. True True – both statements are true but the reason does not explain the assertion
C. True False
D. False True
E. False False

16. Question

Assertion: Revlimid is successfully used to treat myeloma

BECAUSE

Reason: Revlimid has immunomodulatory effects

A. True True – reason correctly explains assertion
B. True True – both statements are true but the reason does not explain the assertion
C. True False
D. False True
E. False False

17. Question

Dexamethasone can cause changes in blood sugar levels and induce diabetes in some myeloma patients

A. True
B. False

18. Question

Lenalidomide (Revlimid®) maintenance treatment has proven to be much better tolerated than thalidomide

A. True
B. False

19. Question

Any treatment combination incorporating an immunomodulatory drug with a steroid increases the risk of

Peripheral neuropathy
Constipation
Hair loss
Venous thromboembolism
Nausea and sickness

20. Question

What does NICE stand for?

A. National Institute for Clinical Excellence
B. National Institute for Chemotherapy Excellence
C. National Institute for Health and Care Excellence
D. National Institute for Health and Clinical Excellence
E. Northern Institute for Clinical Excellence